INBX logo

Inhibrx Biosciences Inc. (INBX)

$87.01

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on INBX

Market cap

$1.28B

EPS

-8.39

P/E ratio

--

Price to sales

1451.85

Dividend yield

--

Beta

2.818603

Price on INBX

Previous close

$91.25

Today's open

$90.08

Day's range

$85.48 - $92.73

52 week range

$12.80 - $155.29

Profile about INBX

CEO

Mark P. Lappe

Employees

161

Headquarters

La Jolla, CA

Exchange

Nasdaq Global Select

Shares outstanding

14671186

Issue type

Common Stock

INBX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on INBX

Inhibrx Reports First Quarter 2026 Financial Results

SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.

news source

PRNewsWire • May 14, 2026

news preview

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and deeper tumor reductions versus KEYTRUDA alone.

news source

MarketBeat • May 11, 2026

news preview

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR. Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.

news source

PRNewsWire • May 11, 2026

news preview

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is reporting positive interim results from its Phase 2 study of INBRX-106 in combination with Merck & Co. Inc.'s (NYSE:MRK) Keytruda (pembrolizumab) for treating head and neck cancer.

news source

Benzinga • May 11, 2026

news preview

This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.

Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment.

news source

Barrons • May 11, 2026

news preview

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m.

news source

PRNewsWire • May 8, 2026

news preview

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.

news source

Zacks Investment Research • Apr 23, 2026

news preview

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA and Japan's Ono Pharmaceutical for an experimental cancer ​treatment that could be valued at more than $8 billion, people familiar with the matter said.

news source

Reuters • Apr 22, 2026

news preview

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion.

news source

Benzinga • Apr 22, 2026

news preview

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs of INBRX-106 and possibly a second asset. Ozekibart's Phase 2 data in chondrosarcoma showed a 52% risk reduction in progression or death, positioning INBX as a first-mover in an unmet oncology market. INBRX-106, in combination with Keytruda, is advancing through Phase 2/3 trials, with key data readouts and potential spinoff partnerships as near-term catalysts.

news source

Seeking Alpha • Apr 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Inhibrx Biosciences Inc.

Open an M1 investment account to buy and sell Inhibrx Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in INBX on M1